CBD shows promise for easing early psychosis symptoms

NCT ID NCT04411225

Recruiting now Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding cannabidiol (CBD) to standard treatment can improve symptoms, thinking, and inflammation in people with early psychosis. About 120 adolescents and adults will receive either CBD or a placebo for 8 weeks. Researchers will also explore what factors influence CBD's effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) oral solution
What this could lead to: If it works, this could point toward a safe, non-psychoactive add-on treatment to ease symptoms and improve thinking in early psychosis.
What could go wrong: This is still an early-phase trial with only 120 people, so results may not apply broadly. CBD may not outperform placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY PSYCHOSIS

Contacts and locations

Locations

UC San Diego
RECRUITING

La Jolla, California, 92093, United States
University of California, San Diego
RECRUITING

San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.